Probmet Therapeutics was established in 2022 in Denmark as a university spin-out from The Royal College of Surgeons in Ireland and is currently incubated at the BioInnovation Institute in Copenhagen. We are a precision oncology therapeutics company that is developing targeted treatments for breast cancer brain metastatic patients. 

Every year 1.7 million women were diagnosed with primary breast cancer.
In almost 700,000 people it will spread beyond the breast to other parts of the body including the brain, lungs, liver and bone. There is a lack of effective targeted therapies available to these patients. 

The current management strategy for patients with metastases are incremental changes of existing therapies that were designed for the primary tumour and not specifically for the metastatic tumours. In addition, in many cases the tumours have developed resistance to currently available therapies and therefore a different approach to uncover new therapeutic targets for these patients is needed.

Brain metastases is particularly difficult to treat due to the blood-brain barrier preventing substances being delivered to the central nervous system.